
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is recognized for its potential in the precision medicine sector, particularly with its lead candidate, stenoparib, which has demonstrated promising clinical benefits for patients with advanced recurrent ovarian cancer, showcasing a median overall survival exceeding 25 months in recent trials. The company’s utilization of proprietary Drug Response Predictor (DRP) technology further enhances its ability to target patients effectively, aiming to improve clinical outcomes significantly. With an attractive current valuation underscored by a positive net present value (NPV) analysis and substantial upside potential from the current share price, Allarity Therapeutics positions itself favorably within the competitive landscape of cancer therapeutics.
Bears say
The financial report indicates a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which is slightly better than prior estimates but still indicative of ongoing financial challenges. Historical losses also reflect consistent negativity, with the previous net loss at $2.37 million and an EPS of $(0.15), raising concerns about sustainability and financial health in a clinical-stage company reliant on successful product development. Moreover, substantial risks related to the balance sheet, regulatory approvals, and competitive pressures further exacerbate uncertainties, contributing to a negative outlook for Allarity Therapeutics's stock performance.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares